The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Despite a significant net loss, GRAIL Inc (GRAL) reports strong revenue growth and strategic collaborations, setting the stage for future advancements.

Q4 2024 Management View CEO Bob Ragusa highlighted 2024 as a transformative year for the company, noting the separation from Illumina and the launch of public trading in June. He mentioned that U.S.

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 19, 2025 /PRNewswire/ -- USA News Group News Commentary - Amid the excitement surrounding ...

Detailed price information for Quest Diagnostics Inc (DGX-N) from The Globe and Mail including charting and trades.

The local sector of test makers, specialized equipment manufacturers and testing product suppliers remain invested in their ...

JPMorgan Chase JPM.N said on Thursday that long-serving CEO Jamie Dimon's 2024 pay package climbed about 8.3% to $39 million after the bank posted a record profit amid a revival in dealmaking ...